Oramed Pharmaceuticals (NSDQ:ORMP) said today that the FDA scheduled an end-of-phase II meeting with the Jerusalem-based company for August 31.
Oramed is developing an oral insulin capsule for the treatment of Type II diabetes. The company’s Phase IIb trial met primary and secondary endpoints, since the insulin capsule lowered patients’ blood sugar relative to a placebo.
Get the full story at our sister site, Drug Delivery Business News.
The post Oramed to meet with FDA about late-stage clinical program for oral insulin capsule appeared first on MassDevice.